CareDx appoints UCSF Health CEO Suresh Gunasekaran to board

SOUTH SAN FRANCISCO - CareDx, Inc. (NASDAQ:CDNA), a precision medicine company focused on diagnostic solutions for transplant patients with annual revenue of $340.83 million and a market capitalization of $780.31 million, announced Wednesday the appointment of Suresh Gunasekaran to its Board of Directors. According to InvestingPro analysis, the company maintains strong financial health with a solid balance sheet and healthy gross margins of 67%.

Gunasekaran currently serves as President and Chief Executive Officer at UCSF Health, a medical system known for specialized care including organ and bone marrow transplantation. He leads an organization with over $9 billion in annual revenue and 20,000 employees. CareDx’s appointment comes at a time when the company shows strong operational efficiency, with InvestingPro data indicating a healthy current ratio of 3.3 and minimal debt exposure.

"I am excited to join the Board of Directors of CareDx, a genomics company with a deep commitment to improving outcomes for transplant patients and supporting the teams that deliver the care," said Gunasekaran.

Prior to his role at UCSF Health, Gunasekaran served as CEO of University of Iowa Hospitals & Clinics and held leadership positions at UT Southwestern Medical Center, Healthlink/IBM, Gartner, and Vanderbilt Children’s Hospital.

John Hanna, President and Chief Executive Officer of CareDx, stated that Gunasekaran’s "voice as a health system leader with a deep commitment to high quality patient care and clinical innovation will be invaluable" to the company’s mission.

The appointment brings more than 20 years of executive leadership experience in healthcare administration and information technology to CareDx’s board, according to the company’s press release statement.

CareDx, headquartered in Brisbane, California, develops and commercializes diagnostic solutions for transplant patients and caregivers. Currently trading below its Fair Value according to InvestingPro analysis, the company shows promising fundamentals with multiple additional insights available through InvestingPro’s comprehensive research reports.

In other recent news, CareDx, Inc. has introduced new innovations in transplant diagnostics at the ASHI 2025 Annual Meeting, including the AlloSeq Tx11, which enhances HLA typing solutions, and the SCORE 7 Software for rapid HLA typing analysis. Additionally, CareDx announced European regulatory certifications for its HLA typing products. BTIG has reiterated its Buy rating on CareDx, maintaining a $22.00 price target, noting potential upside beyond an anticipated CMS decision. Despite concerns over Medicare reimbursement, BTIG has adjusted its price target from $26.00 to $22.00 while maintaining a Buy rating, highlighting that CareDx’s quarterly results aligned with expectations and the company has tightened its full-year guidance. William Blair initiated coverage on CareDx with a Market Perform rating, acknowledging recent business challenges such as reimbursement difficulties and executive changes. These developments underscore the ongoing interest and analysis from research firms regarding CareDx’s future potential and current challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.